Contraindications to Fleet Enema (Sodium Phosphate Enema)
Fleet enemas and all sodium phosphate enemas are absolutely contraindicated in patients with neutropenia, thrombocytopenia, paralytic ileus, intestinal obstruction, recent colorectal or gynecological surgery, recent anal or rectal trauma, severe colitis, toxic megacolon, undiagnosed abdominal pain, and recent pelvic radiotherapy. 1
Absolute Contraindications
The 2018 ESMO Clinical Practice Guidelines provide the most comprehensive list of contraindications for enemas (including Fleet/sodium phosphate enemas):
- Neutropenia (specifically WBC <0.5 cells/µL) 1
- Thrombocytopenia 1, 2
- Paralytic ileus or intestinal obstruction 1
- Recent colorectal or gynecological surgery 1
- Recent anal or rectal trauma 1
- Severe colitis, inflammation or infection of the abdomen 1
- Toxic megacolon 1
- Undiagnosed abdominal pain 1
- Recent radiotherapy to the pelvic area 1
High-Risk Populations Requiring Extreme Caution or Avoidance
Sodium phosphate enemas should be used with extreme caution or avoided entirely in:
Renal Impairment
- Patients with renal dysfunction or chronic kidney disease are at high risk for acute phosphate nephropathy, severe hyperphosphatemia, and potentially fatal electrolyte disturbances 2, 3, 4, 5
- Sodium phosphate should be limited to maximum once daily dosing in patients at risk for renal dysfunction, though alternative agents are strongly preferred 2
Age Extremes
- Children under 2 years: DO NOT USE per FDA labeling 6
- Elderly patients (>65 years): 25% of adverse events occur in this population, with increased risk of fecal incontinence, electrolyte disturbances, and mortality 3, 7
- Children under 18 years: 66% of adverse events occur in pediatric patients 7
Specific Pediatric Conditions
- Children under 12 years with any kidney disease 8
- Hirschsprung disease: particularly high risk for toxicity 3
- Children on medications affecting renal function 8
- Children with significant comorbidities (liver disease, hypertension, hypoparathyroidism, diabetes, heart disease) 8
Cardiovascular and Fluid Status
- Congestive heart failure or cardiovascular disease 4, 9
- Patients at risk for dehydration or electrolyte imbalance 8
- Patients on therapeutic or prophylactic anticoagulation (risk of bleeding complications or intramural hematomas) 1
Gastrointestinal Disorders
- Bowel obstruction or poor gut motility 4, 9
- Small intestinal disorders 4, 9
- Gastrointestinal motility disorders (63% of patients with adverse effects had these conditions) 7
Critical Safety Considerations
Mechanism of Toxicity
Sodium phosphate enemas cause toxicity through massive phosphate absorption leading to:
- Severe hyperphosphatemia 3, 4
- Hypocalcemia (including tetany and coma) 4
- Acute phosphate nephropathy 5
- QT prolongation 3
- Cardiovascular collapse 3
Factors Increasing Absorption and Toxicity
- Enema retention (prolonged retention dramatically increases phosphate absorption) 3
- Inappropriately high doses 3
- Repeated dosing (should not exceed once daily) 2
Mortality Risk
A systematic review identified 12 deaths associated with sodium phosphate enemas, primarily due to electrolyte disturbances, heart failure, and kidney injury 7. More recent literature reports 7 additional adult deaths 3.
Clinical Presentation of Toxicity
In children: Decreased consciousness (6/9 cases), tetany (4/9 cases) 3
In adults: Hypotension (4/5 cases), QT prolongation (2/5 cases) 3
Safer Alternatives
When enemas are necessary in high-risk patients, use:
- Normal saline enemas 1
- Tap water enemas 2, 4
- Osmotic micro-enemas (sorbitol-based) 1
- Docusate sodium enemas 1
These alternatives avoid the risk of systemic phosphate absorption and associated metabolic catastrophes 4.
Common Pitfalls to Avoid
- Over-the-counter availability creates false sense of safety: Fleet enemas are available OTC but can be lethal in at-risk populations 3, 10
- Assuming "adverse events are uncommon": While the ESMO guidelines note AEs are uncommon with hypertonic sodium phosphate enemas 1, this applies only to appropriate patient selection
- Ignoring retention time: Even appropriate doses become toxic if retained 3
- Using in elderly with "mild" renal impairment: Any degree of renal dysfunction increases risk substantially 5